Bill Gates raises concerns over U.S. aid cuts' impact on HIV programs in Africa and calls for a reversal of the decision.

Rashad Burgess is the Executive Director for HIV Community Operations at Gilead Sciences. He spoke with Kayla Thompson about importance of screening, health, and more!

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

Trump administration funding cuts and dismantling of USAID force a shift from HIV elimination back to treatment.

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

The first lenacapavir jabs will be delivered later this year under a new agreement between Gilead Sciences and the Global Fund ...